Limited resection for duodenal gastrointestinal stromal tumors: Surgical management and clinical outcome

Table 3 Adjuvant therapy, pathological features and follow-up

Patient no.	c-KIT	Tumor size (mm)	Mitotic count (/50 HPF)	Risk	Neoadj. therapy	Adjuvant therapy	Disease relapse	Status
1	pos.	32	5	Low risk	No	No	No	NED at 6 mo
2	pos.	35	14	High risk	No	Imatinib	No	NED at 7 mo
3	pos.	14	1	Very low risk	No	No	No	NED at 13 mo
4	pos.	110	35	High risk	No	No	Liver	Died of PD at 3 mo
5	pos.	30	0	Low risk	No	No	No	NED at 90 mo
6	pos.	25	0	Low risk	No	No	No	NED at 111 mo
7	pos.	110	4	High risk	No	No	No	NED at 92 mo
8	pos.	50	0	Low risk	Imatinib	No	No	Died with NED at 37 mo
9	pos.	80	1	Intermediate	Imatinib	Imatinib	No	NED at 39 mo

HPF: High-power field; NED: No evidence of disease; pos: Positive; PD: Progressive disease.